Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · Grayscale

Defiance Autism Impact ETF (ASD)

Ticker ASD · · Holdings as of Jun 30, 2026

Expense ratio
0.79%$79/yr per $10k
Net assets
$1.4Mall share classes
Holdings
39

Bottom line

Is ASD a good fund? The bottom line

ASD is an actively managed large blend ETF from Grayscale.

Its expense ratio is 0.79% — about $79 a year on every $10,000 invested, cheaper than 52% of large blend funds we track.

With $1.4 million in net assets and 39 holdings, its largest position is Definium Therapeutics Inc (4.8%) and the top 10 make up 30.8% of the portfolio.

What to watch

  • Small fund ($1.4 million) — small funds are likelier to close

Updated Nov 19, 2026

What ASD invests in

The Defiance Autism Impact ETF (the Fund or the Autism ETF) seeks to track the total return performance, before fees and expenses, of the VettaFi Autism Impact Index (the Index).

The Fund uses a passive management (or indexing) approach to track the total return performance, before fees and expenses, of the Index. VettaFi Autism Impact Index The Index is designed to measure the performance of publicly traded global companies in developed markets that provide products, services and/or research supporting the autism ecosystem comprised of individuals on the autism spectrum and within the broader neurodivergent community (Autism Impact Companies). The Index seeks to provide diversified exposure to Autism Impact Companies operating across healthcare, pharmaceuticals, biotechnology, behavioral services, diagnostics, specialized education, and assistive technologies that address autism spectrum disorder (ASD) and related neurodevelopmental conditions. VettaFi LLC (VettaFi or the Index Provider), the index provider, selects and maintains the eligible Index universe.…

From the fund's prospectus (filed May 28, 2026).

What ASD costs

On a $10,000 investment, ASD's 0.79% expense ratio costs about $79 a year. The median large blend fund charges 0.83%.

See the full ASD fee table →

ASD top 10 holdings

#Holding% of fund
1Definium Therapeutics Inc DFTX4.77%
2Neuren Pharmaceuticals Ltd NEU3.23%
3LifeStance Health Group Inc LFST3.04%
4Otsuka Holdings Co Ltd 45782.95%
5Acadia Healthcare Co Inc ACHC2.90%
6ACADIA Pharmaceuticals Inc ACAD2.89%
7MapLight Therapeutics Inc MPLT2.89%
8AbbVie Inc ABBV2.72%
9BrightSpring Health Services I BTSG2.70%
10Revvity Inc RVTY2.68%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 30.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to ASD

More funds like ASD →

ASD FAQ

What is the expense ratio of ASD?
ASD's expense ratio is 0.79%, which works out to about $79 a year for every $10,000 invested.
Is ASD a good investment?
It depends on your goals, but the data points to: small fund ($1.4 million) — small funds are likelier to close. This is general information, not personalized advice.
What does ASD hold?
ASD's largest holdings are Definium Therapeutics Inc (4.8%), Neuren Pharmaceuticals Ltd (3.2%), LifeStance Health Group Inc (3.0%), Otsuka Holdings Co Ltd (3.0%), Acadia Healthcare Co Inc (2.9%). It holds 39 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages ASD?
ASD is offered by Grayscale through ETF Series Solutions.